Luminex Co. (NASDAQ:LMNX) – Research analysts at William Blair lowered their Q1 2020 earnings per share (EPS) estimates for Luminex in a research report issued to clients and investors on Tuesday, February 11th. William Blair analyst B. Weinstein now anticipates that the medical instruments supplier will earn ($0.03) per share for the quarter, down from their prior forecast of ($0.01). William Blair also issued estimates for Luminex’s Q4 2020 earnings at $0.06 EPS.
Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, February 10th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.08. The company had revenue of $90.50 million during the quarter, compared to analysts’ expectations of $90.27 million. Luminex had a negative net margin of 1.18% and a negative return on equity of 2.03%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.04 earnings per share.
Luminex stock opened at $23.72 on Thursday. The stock has a market capitalization of $1.09 billion, a PE ratio of -263.56 and a beta of 0.83. Luminex has a twelve month low of $17.34 and a twelve month high of $26.82. The company has a quick ratio of 2.17, a current ratio of 3.52 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average of $23.22 and a 200-day moving average of $21.40.
In other Luminex news, Director G Walter Loewenbaum II bought 2,955 shares of Luminex stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average price of $19.80 per share, for a total transaction of $58,509.00. Following the completion of the acquisition, the director now owns 584,551 shares of the company’s stock, valued at approximately $11,574,109.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.70% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Simplex Trading LLC boosted its holdings in Luminex by 512.6% during the fourth quarter. Simplex Trading LLC now owns 2,089 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 1,748 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in Luminex during the fourth quarter worth $49,000. PNC Financial Services Group Inc. boosted its holdings in Luminex by 23.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,451 shares of the medical instruments supplier’s stock worth $56,000 after purchasing an additional 470 shares during the last quarter. Aigen Investment Management LP acquired a new position in Luminex during the fourth quarter worth $134,000. Finally, Victory Capital Management Inc. boosted its holdings in Luminex by 32.8% during the fourth quarter. Victory Capital Management Inc. now owns 9,252 shares of the medical instruments supplier’s stock worth $214,000 after purchasing an additional 2,287 shares during the last quarter. Institutional investors and hedge funds own 80.85% of the company’s stock.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.